The CELF4 antibody targets the CELF4 protein, a member of the CUGBP Elav-like family (CELF) of RNA-binding proteins. CELF4. also known as BRUNOL4. plays critical roles in post-transcriptional gene regulation, including mRNA splicing, editing, stability, and translation. It is highly expressed in the brain, particularly in neurons, where it influences synaptic plasticity, neuronal development, and function. Dysregulation of CELF4 has been implicated in neurodevelopmental and neurological disorders, such as autism spectrum disorders (ASD), intellectual disability, and epilepsy. Studies also link CELF4 to amyotrophic lateral sclerosis (ALS) due to its interaction with RNA-processing pathways disrupted in neurodegeneration.
CELF4 antibodies are essential tools for investigating its expression, localization, and molecular interactions in both healthy and diseased states. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein levels in tissues or cultured cells. Research utilizing CELF4 antibodies has helped uncover its role in modulating ion channel expression and neurotransmitter receptor trafficking, which may underlie seizure susceptibility and cognitive deficits. Additionally, these antibodies aid in exploring CELF4’s involvement in circadian rhythm regulation and stress granule formation, highlighting its multifaceted impact on cellular physiology. By enabling precise detection and functional studies, CELF4 antibodies contribute to advancing our understanding of its pathological mechanisms and potential therapeutic targets.